Darla R. Shores
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Darla R. Shores has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Jennifer Fundora
Department of Pediatrics, Johns Hopkins Hospital, 1800 Orleans St, Ste 8520, Baltimore, MD, 21287, USA
3 shared publicationsAllen D. Everett
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287
2 shared publicationsAllen Everett
Department of Pediatrics, Division of Cardiology, Johns Hopkins School of Medicine, 720 Rutland Ave, Ross 1143, Baltimore, MD, 21205, USA
2 shared publicationsChhinder P. Sodhi
Department of Surgery, Division of General Pediatric Surgery, Johns Hopkins School of Medicine, 1800 Orleans Street, Room 7337, Baltimore, MD, 21287, USA
2 shared publicationsDavid J. Hackam
Department of Surgery, Division of General Pediatric Surgery, Johns Hopkins School of Medicine, 1800 Orleans Street, Room 7337, Baltimore, MD, 21287, USA
2 shared publicationsFauzia Shakeel
Department of Pediatrics, Division of Maternal Fetal and Neonatal Institute Johns Hopkins All Children's Hospital, 601 5th Street South, St. Petersburg, FL, 33701, USA
2 shared publications
Latest Publications
- 21 June 2022
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 75 (4) , 396-399
Gastroschisis for the Gastroenterologist
Gastroschisis is a common congenital abdominal wall defect, likely influenced by environmental factors in utero, with increasing prevalence in the United States. Early detection of gastroschisis in utero has become the standard with improved prenatal care and screening. There are multiple surgical management techniques, though sutureless closure is being used more frequently. Postoperative feeding difficulty is common and requires vigilance for complications, such as necrotizing enterocolitis. Infants with simple gastroschisis are expected to have eventual catch‐up growth and normal development, while those with complex gastroschisis have higher morbidity and mortality. Management requires collaboration amongst several perinatal disciplines, including obstetrics, maternal fetal medicine, neonatology, pediatric surgery, and pediatric gastroenterology for optimal care and long‐term outcomes.
- 21 June 2022
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 75 (4) , 396-399
Gastroschisis for the Gastroenterologist
Gastroschisis is a common congenital abdominal wall defect, likely influenced by environmental factors in utero, with increasing prevalence in the United States. Early detection of gastroschisis in utero has become the standard with improved prenatal care and screening. There are multiple surgical management techniques, though sutureless closure is being used more frequently. Postoperative feeding difficulty is common and requires vigilance for complications, such as necrotizing enterocolitis. Infants with simple gastroschisis are expected to have eventual catch‐up growth and normal development, while those with complex gastroschisis have higher morbidity and mortality. Management requires collaboration amongst several perinatal disciplines, including obstetrics, maternal fetal medicine, neonatology, pediatric surgery, and pediatric gastroenterology for optimal care and long‐term outcomes.
- 18 March 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (3) , 863-871
Galectin-4 as a Novel Biomarker of Neonatal Intestinal Injury
Background Neonates are at risk of gastrointestinal emergencies including necrotizing enterocolitis (NEC) and spontaneous intestinal perforation (SIP). Identifying biomarkers to aid in diagnosis is imperative. We hypothesized that circulating intestinal-specific protein concentrations would distinguish infants with intestinal injury from controls. Aims To identify serum concentrations of intestinal-specific protein(s) in infants with intestinal injury and controls. Methods We used an in silico approach to identify intestinal-specific proteins. We collected serum from control infants and infants with NEC or SIP and measured protein concentrations using ELISA. If baseline concentrations were near the detection limit in initial control assays, we proceeded to assess concentrations in a larger cohort of controls and infants with injury. Control infants were frequency matched to infants with injury and compared with nonparametric and mixed-effects models analysis. Results We evaluated four proteins with high intestinal expression: Galectin-4 (Gal-4), S100G, Trefoil Factor-3, and alanyl aminopeptidase. Only Gal-4 demonstrated consistent results near the lower limit of quantification in controls and was studied in the larger cohorts. Gal-4 concentration was low in 111 control infants (median 0.012 ng/ml). By contrast, Gal-4 was significantly increased at diagnosis in infants with surgical NEC and SIP (n = 14, p ≤ 0.001 and n = 8, p = 0.031) compared to matched controls, but not in infants with medical NEC (n = 32, p = 0.10). Conclusions Of the intestinal-specific proteins evaluated, circulating Gal-4 concentrations were at the assay detection limit in control infants. Gal-4 concentrations were significantly elevated in infants with surgical NEC or SIP, suggesting that Gal-4 may serve as a biomarker for neonatal intestinal injury.
- 18 March 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (3) , 863-871
Galectin-4 as a Novel Biomarker of Neonatal Intestinal Injury
Background Neonates are at risk of gastrointestinal emergencies including necrotizing enterocolitis (NEC) and spontaneous intestinal perforation (SIP). Identifying biomarkers to aid in diagnosis is imperative. We hypothesized that circulating intestinal-specific protein concentrations would distinguish infants with intestinal injury from controls. Aims To identify serum concentrations of intestinal-specific protein(s) in infants with intestinal injury and controls. Methods We used an in silico approach to identify intestinal-specific proteins. We collected serum from control infants and infants with NEC or SIP and measured protein concentrations using ELISA. If baseline concentrations were near the detection limit in initial control assays, we proceeded to assess concentrations in a larger cohort of controls and infants with injury. Control infants were frequency matched to infants with injury and compared with nonparametric and mixed-effects models analysis. Results We evaluated four proteins with high intestinal expression: Galectin-4 (Gal-4), S100G, Trefoil Factor-3, and alanyl aminopeptidase. Only Gal-4 demonstrated consistent results near the lower limit of quantification in controls and was studied in the larger cohorts. Gal-4 concentration was low in 111 control infants (median 0.012 ng/ml). By contrast, Gal-4 was significantly increased at diagnosis in infants with surgical NEC and SIP (n = 14, p ≤ 0.001 and n = 8, p = 0.031) compared to matched controls, but not in infants with medical NEC (n = 32, p = 0.10). Conclusions Of the intestinal-specific proteins evaluated, circulating Gal-4 concentrations were at the assay detection limit in control infants. Gal-4 concentrations were significantly elevated in infants with surgical NEC or SIP, suggesting that Gal-4 may serve as a biomarker for neonatal intestinal injury.
- Open Access
- 26 May 2020
- Published by Springer Nature in BMC Pediatrics
- Vol. 20 (1) , 1-7
Normative values for circulating intestinal fatty acid binding protein and calprotectin across gestational ages
Background: Necrotizing enterocolitis (NEC) is associated with significant morbidity and mortality. Serum biomarkers to aid diagnosis, such as intestinal fatty acid binding protein (IFABP) and calprotectin, are actively being investigated; however, the normative values of these markers among healthy premature and term infants remains unknown. We sought to identify normative values for the serum concentrations of IFABP and calprotectin across gestational (GA) and post-menstrual age. Methods: We collected serum from infants (24–40 weeks GA) in the first week of life and at multiple time points in a sub-cohort of premature infants (24–29 weeks GA), excluding sepsis or known intestinal disease. IFABP and calprotectin were measured using ELISA. Groups were compared with descriptive statistics and mixed effects linear regression. Results: One hundred twelve infants had specimens in the first week of life, and 19 premature infants had longitudinal specimens. IFABP concentration in the first week of life was low and did not differ across gestational ages. Longitudinally, IFABP increased 4% per day (P < 0.001). Calprotectin concentration in the first week of life was more variable. An inverse relationship between day of life and calprotectin level was found in the longitudinal cohort (P < 0.001). Conclusions: Serum IFABP and calprotectin fluctuate over time. Infants had low levels of IFABP during the first week of life, independent of gestational age, and levels increased longitudinally in premature infants. Calprotectin levels generally declined over time. Normative data for infants is necessary to establish meaningful cut-off levels for clinical use.
- 26 May 2020
- Published by Springer Nature in BMC Pediatrics
- Vol. 20 (1) , 1-7
Open AccessNormative values for circulating intestinal fatty acid binding protein and calprotectin across gestational ages
Background: Necrotizing enterocolitis (NEC) is associated with significant morbidity and mortality. Serum biomarkers to aid diagnosis, such as intestinal fatty acid binding protein (IFABP) and calprotectin, are actively being investigated; however, the normative values of these markers among healthy premature and term infants remains unknown. We sought to identify normative values for the serum concentrations of IFABP and calprotectin across gestational (GA) and post-menstrual age. Methods: We collected serum from infants (24–40 weeks GA) in the first week of life and at multiple time points in a sub-cohort of premature infants (24–29 weeks GA), excluding sepsis or known intestinal disease. IFABP and calprotectin were measured using ELISA. Groups were compared with descriptive statistics and mixed effects linear regression. Results: One hundred twelve infants had specimens in the first week of life, and 19 premature infants had longitudinal specimens. IFABP concentration in the first week of life was low and did not differ across gestational ages. Longitudinally, IFABP increased 4% per day (P < 0.001). Calprotectin concentration in the first week of life was more variable. An inverse relationship between day of life and calprotectin level was found in the longitudinal cohort (P < 0.001). Conclusions: Serum IFABP and calprotectin fluctuate over time. Infants had low levels of IFABP during the first week of life, independent of gestational age, and levels increased longitudinally in premature infants. Calprotectin levels generally declined over time. Normative data for infants is necessary to establish meaningful cut-off levels for clinical use.
- Open Access
- 19 May 2020
- Published by Springer Nature in Research Square
Normative Values For Circulating Intestinal Fatty Acid Binding Protein And Calprotectin Across Gestational Ages
Background: Necrotizing enterocolitis (NEC) is associated with significant morbidity and mortality. Serum biomarkers to aid diagnosis, such as intestinal fatty acid binding protein (IFABP) and calprotectin, are actively being investigated; however, the normative values of these markers among healthy premature and term infants remains unknown.Aims: We sought to identify normative values for the serum concentrations of IFABP and calprotectin across gestational (GA) and post-menstrual age.Methods: We collected serum from infants (24-40 weeks GA) in the first week of life and at multiple time points in a sub-cohort of premature infants (24-29 weeks GA), excluding sepsis or known intestinal disease. IFABP and calprotectin were measured using ELISA. Groups were compared with descriptive statistics and mixed effects linear regression.Results: 112 infants had specimens in the first week of life, and 19 premature infants had longitudinal specimens. IFABP concentration in the first week of life was low and did not differ across gestational ages. Longitudinally, IFABP increased 4% per day (PConclusions: Serum IFABP and calprotectin fluctuate over time. Infants had low levels of IFABP during the first week of life, independent of gestational age, and levels increased longitudinally in premature infants. Calprotectin levels generally declined over time. Normative data for infants is necessary to establish meaningful cut-off levels for clinical use.
- 19 May 2020
- Published by Springer Nature in Research Square
Open AccessNormative Values For Circulating Intestinal Fatty Acid Binding Protein And Calprotectin Across Gestational Ages
Background: Necrotizing enterocolitis (NEC) is associated with significant morbidity and mortality. Serum biomarkers to aid diagnosis, such as intestinal fatty acid binding protein (IFABP) and calprotectin, are actively being investigated; however, the normative values of these markers among healthy premature and term infants remains unknown.Aims: We sought to identify normative values for the serum concentrations of IFABP and calprotectin across gestational (GA) and post-menstrual age.Methods: We collected serum from infants (24-40 weeks GA) in the first week of life and at multiple time points in a sub-cohort of premature infants (24-29 weeks GA), excluding sepsis or known intestinal disease. IFABP and calprotectin were measured using ELISA. Groups were compared with descriptive statistics and mixed effects linear regression.Results: 112 infants had specimens in the first week of life, and 19 premature infants had longitudinal specimens. IFABP concentration in the first week of life was low and did not differ across gestational ages. Longitudinally, IFABP increased 4% per day (PConclusions: Serum IFABP and calprotectin fluctuate over time. Infants had low levels of IFABP during the first week of life, independent of gestational age, and levels increased longitudinally in premature infants. Calprotectin levels generally declined over time. Normative data for infants is necessary to establish meaningful cut-off levels for clinical use.
- 4 May 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (20) , 10958-10969
Targeted inhibition of thrombin attenuates murine neonatal necrotizing enterocolitis
Necrotizing enterocolitis (NEC) is an inflammatory bowel necrosis of premature infants and an orphan disease with no specific treatment. Most patients with confirmed NEC develop moderate-severe thrombocytopenia requiring one or more platelet transfusions. Here we used our neonatal murine model of NEC-related thrombocytopenia to investigate mechanisms of platelet depletion associated with this disease [K. Namachivayam, K. MohanKumar, L. Garg, B. A. Torres, A. Maheshwari, Pediatr. Res. 81, 817–824 (2017)]. In this model, enteral administration of immunogen trinitrobenzene sulfonate (TNBS) in 10-d-old mouse pups produces an acute necrotizing ileocolitis resembling human NEC within 24 h, and these mice developed thrombocytopenia at 12 to 15 h. We hypothesized that platelet activation and depletion occur during intestinal injury following exposure to bacterial products translocated across the damaged mucosa. Surprisingly, platelet activation began in our model 3 h after TNBS administration, antedating mucosal injury or endotoxinemia. Platelet activation was triggered by thrombin, which, in turn, was activated by tissue factor released from intestinal macrophages. Compared to adults, neonatal platelets showed enhanced sensitivity to thrombin due to higher expression of several downstream signaling mediators and the deficiency of endogenous thrombin antagonists. The expression of tissue factor in intestinal macrophages was also unique to the neonate. Targeted inhibition of thrombin by a nanomedicine-based approach was protective without increasing interstitial hemorrhages in the inflamed bowel or other organs. In support of these data, we detected increased circulating tissue factor and thrombin-antithrombin complexes in patients with NEC. Our findings show that platelet activation is an important pathophysiological event and a potential therapeutic target in NEC. Significance Necrotizing enterocolitis (NEC) is an inflammatory bowel necrosis of premature infants and is a leading cause of death in these patients. It is an orphan disease with no specific treatment. In this study, we investigated the mechanisms of NEC-related thrombocytopenia, a characteristic feature of this disease. We tested the hypothesis that platelet activation and depletion occur during NEC once mucosal disruption is well established and is secondary to bacterial translocation across the damaged mucosa. Surprisingly, platelet activation turned out to be an early thrombin-mediated pathogenetic event during NEC-like injury. We show that a targeted nanomedicine approach to inhibit thrombin can attenuate NEC-like injury. If confirmed in clinical studies, this would be a specific treatment for NEC.
- 4 May 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (20) , 10958-10969
Targeted inhibition of thrombin attenuates murine neonatal necrotizing enterocolitis
Necrotizing enterocolitis (NEC) is an inflammatory bowel necrosis of premature infants and an orphan disease with no specific treatment. Most patients with confirmed NEC develop moderate-severe thrombocytopenia requiring one or more platelet transfusions. Here we used our neonatal murine model of NEC-related thrombocytopenia to investigate mechanisms of platelet depletion associated with this disease [K. Namachivayam, K. MohanKumar, L. Garg, B. A. Torres, A. Maheshwari, Pediatr. Res. 81, 817–824 (2017)]. In this model, enteral administration of immunogen trinitrobenzene sulfonate (TNBS) in 10-d-old mouse pups produces an acute necrotizing ileocolitis resembling human NEC within 24 h, and these mice developed thrombocytopenia at 12 to 15 h. We hypothesized that platelet activation and depletion occur during intestinal injury following exposure to bacterial products translocated across the damaged mucosa. Surprisingly, platelet activation began in our model 3 h after TNBS administration, antedating mucosal injury or endotoxinemia. Platelet activation was triggered by thrombin, which, in turn, was activated by tissue factor released from intestinal macrophages. Compared to adults, neonatal platelets showed enhanced sensitivity to thrombin due to higher expression of several downstream signaling mediators and the deficiency of endogenous thrombin antagonists. The expression of tissue factor in intestinal macrophages was also unique to the neonate. Targeted inhibition of thrombin by a nanomedicine-based approach was protective without increasing interstitial hemorrhages in the inflamed bowel or other organs. In support of these data, we detected increased circulating tissue factor and thrombin-antithrombin complexes in patients with NEC. Our findings show that platelet activation is an important pathophysiological event and a potential therapeutic target in NEC. Significance Necrotizing enterocolitis (NEC) is an inflammatory bowel necrosis of premature infants and is a leading cause of death in these patients. It is an orphan disease with no specific treatment. In this study, we investigated the mechanisms of NEC-related thrombocytopenia, a characteristic feature of this disease. We tested the hypothesis that platelet activation and depletion occur during NEC once mucosal disruption is well established and is secondary to bacterial translocation across the damaged mucosa. Surprisingly, platelet activation turned out to be an early thrombin-mediated pathogenetic event during NEC-like injury. We show that a targeted nanomedicine approach to inhibit thrombin can attenuate NEC-like injury. If confirmed in clinical studies, this would be a specific treatment for NEC.
- 23 January 2020
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 70 (5) , 657-663
Cost‐effectiveness Analysis of Feeding Guidelines for Infants Following Intestinal Surgery
Objective: The aim of the study was to determine the cost‐effectiveness of postoperative feeding guidelines to reduce complications in infants with intestinal surgery compared to standard feeding practices.Methods: Using outcomes from a cohort study, Markov models from health care and societal perspectives simulated costs per hospitalization among infants fed via guidelines versus standard practice. Short‐term outcomes included intestinal failure–associated liver disease, necrotizing enterocolitis after feeding, sepsis, and mortality. Effectiveness was measured as length of stay. The incremental cost‐effectiveness ratios (ICER) compared cost over length of stay. Univariate and multivariate probabilistic sensitivity analyses with 10,000 Monte Carlo Simulations were performed. A second decision tree model captured the cost per quality‐adjusted life years (QALYs) using utilities associated with long‐term outcomes (liver cirrhosis and transplantation).Results: In the hospital perspective, standard feeding had a cost of $31,258,902 and 8296 hospital days, and the feeding guidelines had a cost of $29,295,553 and 8096 hospital days. The ICER was $−9832 per hospital stay with guideline use. More than 90% of the ICERs were in the dominant quadrant. Results were similar for the societal perspective. Long‐term costs and utilities in the guideline group were $2830 and 0.91, respectively, versus $4030 and 0.90, resulting in an ICER of $−91,756/QALY.Conclusion: In our models, feeding guideline use resulted in cost savings and reduction in hospital stay in the short‐term and cost savings and an increase in QALYs in the long‐term. Using a systematic approach to feed surgical infants appears to reduce costly complications, but further data from a larger cohort are needed.
- 23 January 2020
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 70 (5) , 657-663
Cost‐effectiveness Analysis of Feeding Guidelines for Infants Following Intestinal Surgery
Objective: The aim of the study was to determine the cost‐effectiveness of postoperative feeding guidelines to reduce complications in infants with intestinal surgery compared to standard feeding practices.Methods: Using outcomes from a cohort study, Markov models from health care and societal perspectives simulated costs per hospitalization among infants fed via guidelines versus standard practice. Short‐term outcomes included intestinal failure–associated liver disease, necrotizing enterocolitis after feeding, sepsis, and mortality. Effectiveness was measured as length of stay. The incremental cost‐effectiveness ratios (ICER) compared cost over length of stay. Univariate and multivariate probabilistic sensitivity analyses with 10,000 Monte Carlo Simulations were performed. A second decision tree model captured the cost per quality‐adjusted life years (QALYs) using utilities associated with long‐term outcomes (liver cirrhosis and transplantation).Results: In the hospital perspective, standard feeding had a cost of $31,258,902 and 8296 hospital days, and the feeding guidelines had a cost of $29,295,553 and 8096 hospital days. The ICER was $−9832 per hospital stay with guideline use. More than 90% of the ICERs were in the dominant quadrant. Results were similar for the societal perspective. Long‐term costs and utilities in the guideline group were $2830 and 0.91, respectively, versus $4030 and 0.90, resulting in an ICER of $−91,756/QALY.Conclusion: In our models, feeding guideline use resulted in cost savings and reduction in hospital stay in the short‐term and cost savings and an increase in QALYs in the long‐term. Using a systematic approach to feed surgical infants appears to reduce costly complications, but further data from a larger cohort are needed.
- 1 July 2019
- Published by Wolters Kluwer Health in Gastroenterology Nursing
- Vol. 42 (4) , 370-374
Utilizing Information Technology to Improve Influenza Vaccination in Pediatric Patients With Inflammatory Bowel Disease
Pediatric patients with inflammatory bowel disease are undervaccinated against influenza. Gastroenterology nurses are ideally situated to assist in improving vaccination in this population. The objective of this quality improvement project was to evaluate the implementation of information technology prompts within the electronic medical record to improve influenza vaccination during specialty clinic visits. The proportion of patients with yearly influenza vaccination was evaluated at baseline, Year 1, and Year 2 following implementation. At baseline, only 10% of a random sample had documented influenza vaccination. Vaccination documentation improved to 39% (96/246) by Year 1 and to 61% (175/287) by Year 2 (p < .001). Vaccine counseling improved from 27% to 77% by Year 2 for unvaccinated patients (p < .001). Among patients seen by gastroenterology nurses, the proportion of patients with either documented vaccination or counseling was 94% by Year 2 compared with 70% if seen only by a physician (p < .001). Documentation of influenza vaccination improved with the use of customized prompts. Patients seen by a gastroenterology nurse had higher vaccination documentation and vaccine counseling than those who were seen by a physician alone.
- 1 July 2019
- Published by Wolters Kluwer Health in Gastroenterology Nursing
- Vol. 42 (4) , 370-374
Utilizing Information Technology to Improve Influenza Vaccination in Pediatric Patients With Inflammatory Bowel Disease
Pediatric patients with inflammatory bowel disease are undervaccinated against influenza. Gastroenterology nurses are ideally situated to assist in improving vaccination in this population. The objective of this quality improvement project was to evaluate the implementation of information technology prompts within the electronic medical record to improve influenza vaccination during specialty clinic visits. The proportion of patients with yearly influenza vaccination was evaluated at baseline, Year 1, and Year 2 following implementation. At baseline, only 10% of a random sample had documented influenza vaccination. Vaccination documentation improved to 39% (96/246) by Year 1 and to 61% (175/287) by Year 2 (p < .001). Vaccine counseling improved from 27% to 77% by Year 2 for unvaccinated patients (p < .001). Among patients seen by gastroenterology nurses, the proportion of patients with either documented vaccination or counseling was 94% by Year 2 compared with 70% if seen only by a physician (p < .001). Documentation of influenza vaccination improved with the use of customized prompts. Patients seen by a gastroenterology nurse had higher vaccination documentation and vaccine counseling than those who were seen by a physician alone.
- 1 February 2019
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 68 (2) , 264-271
Use of Breast Milk and Other Feeding Practices Following Gastrointestinal Surgery in Infants
Objectives: The aim of the study was to characterize the enteral feeding practices in infants after gastrointestinal surgery.Methods: We performed a retrospective analysis of infants who underwent intestinal surgery at age P = 0.004). Donor milk was used in 11%, most commonly in infants with NEC and SIP. Infants with NEC were least likely to continue MM in the hospital (7%, P = 0.0014) and were more likely to receive elemental formula. Only 44% of infants received MM at discharge. After 1 year, 25% were fed MM. The majority of infants were discharged with feeding tubes (nasogastric: 35%, gastric: 23%). Although all groups had acceptable weights at discharge, infants with NEC (z score: −1.8) and SIP (z score: −1.1) showed growth failure at 3 months (z scores: −3.3, −3.2, respectively, P < 0.0001), but had appropriate gain by 1 year (z scores: −1.1, −1.7, respectively).Conclusions: Despite most infants receiving MM in the early postoperative period, <50% at discharge and only 33% at 1‐year still received MM. Weight gain after discharge in infants with NEC and SIP warrants close monitoring.
- 1 February 2019
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 68 (2) , 264-271
Use of Breast Milk and Other Feeding Practices Following Gastrointestinal Surgery in Infants
Objectives: The aim of the study was to characterize the enteral feeding practices in infants after gastrointestinal surgery.Methods: We performed a retrospective analysis of infants who underwent intestinal surgery at age P = 0.004). Donor milk was used in 11%, most commonly in infants with NEC and SIP. Infants with NEC were least likely to continue MM in the hospital (7%, P = 0.0014) and were more likely to receive elemental formula. Only 44% of infants received MM at discharge. After 1 year, 25% were fed MM. The majority of infants were discharged with feeding tubes (nasogastric: 35%, gastric: 23%). Although all groups had acceptable weights at discharge, infants with NEC (z score: −1.8) and SIP (z score: −1.1) showed growth failure at 3 months (z scores: −3.3, −3.2, respectively, P < 0.0001), but had appropriate gain by 1 year (z scores: −1.1, −1.7, respectively).Conclusions: Despite most infants receiving MM in the early postoperative period, <50% at discharge and only 33% at 1‐year still received MM. Weight gain after discharge in infants with NEC and SIP warrants close monitoring.
- 1 April 2018
- Published by Elsevier in The Journal of Pediatrics
- Vol. 195, 140-147.e1
Postoperative Enteral Nutrition Guidelines Reduce the Risk of Intestinal Failure–Associated Liver Disease in Surgical Infants
- 1 April 2018
- Published by Elsevier in The Journal of Pediatrics
- Vol. 195, 140-147.e1
Postoperative Enteral Nutrition Guidelines Reduce the Risk of Intestinal Failure–Associated Liver Disease in Surgical Infants
- 12 October 2017
- Published by Elsevier in The Journal of Pediatrics
- Vol. 193, 14-20.e31
Children as Biomarker Orphans: Progress in the Field of Pediatric Biomarkers
- 12 October 2017
- Published by Elsevier in The Journal of Pediatrics
- Vol. 193, 14-20.e31
Children as Biomarker Orphans: Progress in the Field of Pediatric Biomarkers